サンプル依頼リスト カート
  • English
  • Korean
表紙：増殖糖尿病網膜症（PDR）の世界市場レポート 2024年
市場調査レポート
商品コード
1415658

増殖糖尿病網膜症（PDR）の世界市場レポート 2024年

Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
増殖糖尿病網膜症（PDR）の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

増殖糖尿病網膜症（PDR）の市場規模は近年急速に拡大しています。2023年の21億6,000万米ドルから2024年には24億2,000万米ドルへと、CAGR11.7％で拡大します。歴史的な期間における成長は、糖尿病有病率の増加、ライフスタイルの変化と不健康な食品の摂取、政府の取り組み、糖尿病に関連する視力喪失者数の増加に起因しています。

増殖糖尿病網膜症（PDR）市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR10.6％で36億2,000万米ドルに成長します。予測期間の成長は、人口の高齢化、糖尿病に関する一般市民の認識と教育、研究開発資金、併用療法に対する需要の高まりに起因すると考えられます。予測期間における主な動向には、診断技術の進歩、治療オプションの革新、早期診断のための人工知能（AI）、遺伝子治療の進歩、高度な網膜イメージングなどがあります。

糖尿病有病率の増加は、増殖糖尿病網膜症（PDR）市場の将来的な成長の重要な促進要因になると予測されます。糖尿病は、血糖値の上昇を特徴とする慢性疾患であり、増殖糖尿病網膜症の主な原因となっています。網膜のさらなる損傷を防ぎ、糖尿病患者の視力を維持するために、さまざまな治療法が利用可能です。例えば、ベルギーに本部を置く国際糖尿病連合（IDF）の報告によると、2021年には20～79歳の成人5億3,700万人が糖尿病に罹患し、これは10人に1人に相当します。この数字は、2030年には約6億4300万人に、さらに2045年には7億8300万人に増加すると予測されています。その結果、糖尿病有病率の上昇が増殖糖尿病網膜症（PDR）市場成長の原動力となっています。

肥満の有病率の増加は、増殖糖尿病網膜症（PDR）市場の今後の成長の主要な促進要因になると予想されます。肥満は様々な要因を持つ多面的な慢性疾患であり、体脂肪の過剰蓄積と潜在的な健康問題をもたらします。肥満は、インスリン抵抗性、慢性的な低級炎症、酸化ストレスの高まりと密接に関連しており、これらすべてが網膜微小血管系に悪影響を及ぼし、糖尿病網膜症の発症の一因となる可能性があります。例えば、米国の非営利団体Trust for America's Healthが2022年に発表した報告書によると、米国の肥満率は上昇傾向にあり、米国成人の10人に4人が肥満の影響を受けています。これは前年に比べ増加したことを示しており、成人の肥満率が35％を超えたと報告した州は19州と、前年の16州から増加しています。その結果、肥満の深刻化は増殖糖尿病網膜症（PDR）市場の拡大を促進する極めて重要な触媒となっています。

2023年の増殖糖尿病網膜症（PDR）市場では北米が最大地域でした。アジア太平洋地域は予測期間中に最も急成長する地域となる見込みです。増殖糖尿病網膜症（PDR）レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の増殖糖尿病網膜症（PDR）市場、治療タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗VEGF（血管内皮増殖因子）療法
  • 眼内ステロイド
  • レーザー手術
  • 硝子体手術
  • 世界の増殖糖尿病網膜症（PDR）市場、投与方法別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 注射剤
  • 経口
  • その他
  • 世界の増殖糖尿病網膜症（PDR）市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • クリニック
  • その他

第7章 地域および国の分析

  • 世界の増殖糖尿病網膜症（PDR）市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の増殖糖尿病網膜症（PDR）市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 増殖糖尿病網膜症（PDR）市場の競合情勢
  • 増殖糖尿病網膜症（PDR）市場企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Limited
    • F. Hoffmann-La Roche Ltd.
    • Merck and Co. Inc.
    • AbbVie Inc.

第31章 その他の主要および革新的な企業

  • Bayer AG
  • Novartis AG
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • GSK plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Novo Nordisk A/S
  • Boehringer Ingelheim International GmbH
  • Merck KGaA
  • Kubota Vision Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Regeneron Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12257

“Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on proliferative diabetic retinopathy (pdr) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for proliferative diabetic retinopathy (pdr)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The proliferative diabetic retinopathy (pdr) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy; Intraocular Steroids; Laser Surgery; Vitrectomy
  • 2) By Mode of Administration: Injectables; Oral; Other Mode Of Administrations
  • 3) By Application: Hospitals; Clinics; Other Applications
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; F. Hoffmann-La Roche Ltd.; Merck and Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Proliferative diabetic retinopathy (PDR) represents an advanced stage of diabetic eye disease marked by the development of abnormal blood vessels in the retina. This occurrence is primarily attributed to prolonged high levels of blood sugar. If left unaddressed, these abnormal vessels can result in retinal bleeding, scarring, and impaired vision. Consequently, regular eye examinations are of paramount importance for early detection and effective management.

The primary treatment options for proliferative diabetic retinopathy encompass anti-VEGF (vascular endothelial growth factor) therapy, intraocular steroids, laser surgery, and vitrectomy. Intraocular steroids involve the direct administration of medications into the eye, which serves to address inflammation and manage conditions like diabetic macular edema or uveitis. This approach aids in reducing swelling and enhancing visual outcomes. Various modes of administration, including injectables, oral medications, and others, find application in settings such as hospitals, clinics, and more.

The proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides proliferative diabetic retinopathy market statistics, including proliferative diabetic retinopathy industry global market size, regional shares, competitors with a proliferative diabetic retinopathy market share, detailed proliferative diabetic retinopathy market segments, market trends and opportunities and any further data you may need to thrive in the proliferative diabetic retinopathy industry. This proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proliferative diabetic retinopathy (pdr) market size has grown rapidly in recent years. It will grow from $2.16 billion in 2023 to $2.42 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to growing diabetes prevalence, changes in lifestyle and intake of unhealthy foods, government initiatives, rising numbers of diabetes-related loss of vision.

The proliferative diabetic retinopathy (pdr) market size is expected to see rapid growth in the next few years. It will grow to $3.62 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to aging population, public awareness and education about diabetes, research and development funding, rising demand for combination therapies. Major trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, artificial intelligence (ai) for early diagnosis, gene therapy advancements, advanced retinal imaging.

The increasing prevalence of diabetes is anticipated to be a significant driver for the future growth of the proliferative diabetic retinopathy (PDR) market. Diabetes, a chronic medical condition characterized by elevated blood glucose levels, stands as the primary contributor to proliferative diabetic retinopathy. Various treatments are available to prevent further damage to the retina and preserve vision in individuals with diabetes. For instance, as reported by the International Diabetes Federation (IDF), a Belgium-based organization, the year 2021 witnessed 537 million adults between the ages of 20-79 affected by diabetes, which translates to 1 in 10 people. This number is projected to increase to around 643 million by 2030 and further to 783 million by 2045. As a result, the rising prevalence of diabetes serves as a driving force behind the growth of the proliferative diabetic retinopathy (PDR) market.

The increasing prevalence of obesity is expected to be a key driver for the future growth of the proliferative diabetic retinopathy (PDR) market. Obesity, a multifaceted, chronic condition with various contributing factors, results in an excess accumulation of body fat and potential health issues. Obesity is closely associated with insulin resistance, chronic low-grade inflammation, and heightened oxidative stress, all of which can adversely affect the retinal microvasculature and contribute to the onset of diabetic retinopathy. For instance, according to a 2022 report released by Trust for America's Health, a non-profit organization in the United States, obesity rates in the country are on the rise, with four out of every ten American adults being affected by obesity. This represents an increase compared to the previous year, with 19 states reporting adult obesity rates exceeding 35%, up from 16 states in the preceding year. Consequently, the escalating prevalence of obesity serves as a pivotal catalyst driving the expansion of the proliferative diabetic retinopathy (PDR) market.

High treatment costs serve as a deterrent to the growth of the proliferative diabetic retinopathy (PDR) market during the projected period. The expenses associated with diagnosing and treating PDR can pose a significant financial burden, often reaching prohibitive levels. This encompasses the costs related to frequent eye examinations, laser therapy, and, in certain cases, surgical interventions. These elevated treatment expenses create financial challenges for both patients and healthcare systems. For instance, in 2023, as reported by Medical News Today, individuals typically face annual management costs ranging from $600 to $1,000 for the treatment of diabetic eye disease, while the cost of a vitrectomy procedure falls within the range of $8,000 to $14,000. As a result, the high treatment costs emerge as a constraining factor, impeding the growth of the proliferative diabetic retinopathy (PDR) market.

Prominent companies operating in the proliferative diabetic retinopathy market maintain a consistent focus on the development of groundbreaking therapies. This strategic emphasis aims to enhance treatment efficacy, alleviate the treatment-related financial burden, and ultimately elevate patient outcomes. For instance, in June 2022, Biogen, a leading US-based biotechnology company, partnered with Samsung Bioepis, a South Korea-based biotech company, to introduce Byooviz (ranibizumab-nuna). Byooviz represents the first ophthalmology biosimilar in the United States, offering treatment options for patients dealing with diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization. These innovative therapies are poised to bring transformative changes to the landscape of proliferative diabetic retinopathy treatment.

In September 2021, AbbVie, a pharmaceutical company based in the United States, and REGENXBIO Inc. entered into a collaborative partnership, the financial details of which have not been disclosed. This strategic alliance is driven by a shared objective includes the development and commercialization of RGX-314, a potential one-time gene therapy specifically crafted to address conditions like wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. At present, RGX-314 is undergoing a pivotal trial focused on wet AMD, employing a subretinal administration approach. Simultaneously, separate Phase II clinical trials are underway for both wet AMD and DR, with the utilization of in-office suprachoroidal delivery. Notably, REGENXBIO Inc., a US-based company renowned for its work in developing treatments for proliferative diabetic retinopathy (PDR), plays an integral role in this collaborative effort.

Major players in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

North America was the largest region in the proliferative diabetic retinopathy market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the proliferative diabetic retinopathy (PDR) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The proliferative diabetic retinopathy (PDR) market consists of sales of laser therapy, systemic therapies and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The proliferative diabetic retinopathy (PDR) market also includes sales of corticosteroids, ranibizumab, bevacizumab and fluocinolone acetonide drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Proliferative Diabetic Retinopathy (PDR) Market Characteristics

3. Proliferative Diabetic Retinopathy (PDR) Market Trends And Strategies

4. Proliferative Diabetic Retinopathy (PDR) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Proliferative Diabetic Retinopathy (PDR) Market Size and Growth

  • 5.1. Global Proliferative Diabetic Retinopathy (PDR) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Proliferative Diabetic Retinopathy (PDR) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Proliferative Diabetic Retinopathy (PDR) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Proliferative Diabetic Retinopathy (PDR) Market Segmentation

  • 6.1. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Anti-VEGF (Vascular Endothelial Growth Factor) Therapy
  • Intraocular Steroids
  • Laser Surgery
  • Vitrectomy
  • 6.2. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Injectables
  • Oral
  • Other Mode Of Administrations
  • 6.3. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Other Applications

7. Proliferative Diabetic Retinopathy (PDR) Market Regional And Country Analysis

  • 7.1. Global Proliferative Diabetic Retinopathy (PDR) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Proliferative Diabetic Retinopathy (PDR) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market

  • 8.1. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Proliferative Diabetic Retinopathy (PDR) Market

  • 9.1. China Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 9.2. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Proliferative Diabetic Retinopathy (PDR) Market

  • 10.1. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Proliferative Diabetic Retinopathy (PDR) Market

  • 11.1. Japan Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 11.2. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Proliferative Diabetic Retinopathy (PDR) Market

  • 12.1. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Proliferative Diabetic Retinopathy (PDR) Market

  • 13.1. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Proliferative Diabetic Retinopathy (PDR) Market

  • 14.1. South Korea Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 14.2. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Proliferative Diabetic Retinopathy (PDR) Market

  • 15.1. Western Europe Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 15.2. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Proliferative Diabetic Retinopathy (PDR) Market

  • 16.1. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Proliferative Diabetic Retinopathy (PDR) Market

  • 17.1. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Proliferative Diabetic Retinopathy (PDR) Market

  • 18.1. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Proliferative Diabetic Retinopathy (PDR) Market

  • 19.1. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Proliferative Diabetic Retinopathy (PDR) Market

  • 20.1. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market

  • 21.1. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 21.2. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Proliferative Diabetic Retinopathy (PDR) Market

  • 22.1. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Proliferative Diabetic Retinopathy (PDR) Market

  • 23.1. North America Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 23.2. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Proliferative Diabetic Retinopathy (PDR) Market

  • 24.1. USA Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 24.2. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Proliferative Diabetic Retinopathy (PDR) Market

  • 25.1. Canada Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 25.2. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Proliferative Diabetic Retinopathy (PDR) Market

  • 26.1. South America Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 26.2. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Proliferative Diabetic Retinopathy (PDR) Market

  • 27.1. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Proliferative Diabetic Retinopathy (PDR) Market

  • 28.1. Middle East Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 28.2. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Proliferative Diabetic Retinopathy (PDR) Market

  • 29.1. Africa Proliferative Diabetic Retinopathy (PDR) Market Overview
  • 29.2. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Proliferative Diabetic Retinopathy (PDR) Market Competitive Landscape And Company Profiles

  • 30.1. Proliferative Diabetic Retinopathy (PDR) Market Competitive Landscape
  • 30.2. Proliferative Diabetic Retinopathy (PDR) Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Limited
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck and Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Proliferative Diabetic Retinopathy (PDR) Market Other Major And Innovative Companies

  • 31.1. Bayer AG
  • 31.2. Novartis AG
  • 31.3. Sanofi S.A.
  • 31.4. Bristol-Myers Squibb Company
  • 31.5. AstraZeneca plc
  • 31.6. GSK plc
  • 31.7. Takeda Pharmaceutical Company Limited
  • 31.8. Eli Lilly and Company
  • 31.9. Amgen Inc.
  • 31.10. Novo Nordisk A/S
  • 31.11. Boehringer Ingelheim International GmbH
  • 31.12. Merck KGaA
  • 31.13. Kubota Vision Inc.
  • 31.14. Teva Pharmaceutical Industries Ltd.
  • 31.15. Regeneron Pharmaceuticals Inc.

32. Global Proliferative Diabetic Retinopathy (PDR) Market Competitive Benchmarking

33. Global Proliferative Diabetic Retinopathy (PDR) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Proliferative Diabetic Retinopathy (PDR) Market

35. Proliferative Diabetic Retinopathy (PDR) Market Future Outlook and Potential Analysis

  • 35.1 Proliferative Diabetic Retinopathy (PDR) Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Proliferative Diabetic Retinopathy (PDR) Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Proliferative Diabetic Retinopathy (PDR) Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer